Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Viral-associated cancers and disorders.
Subtyping Burkitt Lymphoma by <scp>DNA</scp> Methylation
<scp>WNT5a</scp> export onto extracellular vesicles studied at single‐molecule and single‐vesicle resolution
The genomic and transcriptional landscape of primary central nervous system lymphoma
Superresolution microscopy localizes endogenous Dvl2 to Wnt signaling-responsive biomolecular condensates
Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
The genomic and transcriptional landscape of primary central nervous system lymphoma
The genomic and transcriptional landscape of primary central nervous system lymphoma
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A modular transcriptome map of mature B cell lymphomas
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2
Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression
Author Correction: Molecular subtypes of diffuse large B celllymphoma are associated with distinct pathogenic mechanisms and outcomes
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
<i>TP53</i> mutation and survival in aggressive B cell lymphoma
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
COMPREHENSIVE EPIGENETIC AND TRANSCRIPTIONAL SURVEY OF THE “IMPRINTOME” IN NORMAL <scp>B</scp>‐CELLS AND GERMINAL CENTER DERIVED <scp>B</scp>‐CELL LYMPHOMAS OF THE <scp>MMML</scp> AND <scp>ICGC MMML‐S</scp>EQ NETWORKS
MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B‐CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML‐SEQ CONSORTIUM
PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML: ICGC AND BLUEPRINT CONSORTIA
B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B‐cell lymphoma